Ozone Pharmaceuticals, looking to double its present turnover in the next two years, will be launching at least 30 more products, mostly targeting the common diseases, under its different verticals and ayurvedic division, its chairman and managing director Subhash Chander Sehgal said.

The group, consisting of pharma and ayurvedic divisions, has clocked Rs 112 crore as turnover during 2006-07 and hopes to post Rs 150 this financial year. "We hope to cross Rs 200 crore mark next year and our aim is to make it Rs 500 crore within five years," Seghal told Pharmabiz.

The fast growing Delhi-based pharma player, which has set up an R&D division to boost its standardisation efforts especially in the ayurvedic arena, is planning to double its portfolio with another 30 products in the next two years. The products will be launched under its specialised verticals for gynaecology, ortho, and cardiology. "We are planning to create a separate specialised vertical for mass-oriented drugs, targeting the seasonal diseases affecting larger population. We will introduce products in therapeutic areas like antibiotics, anti-fungal, anti-infectives and anxiolytics at competitive prices, also targeting mass diseases like diarrhoea," he said.

As part of its standardisation, fine-tuning of drug delivery system and research, it has earmarked Rs 20 crore for its newly-created R&D division. The company, which has two facilities at Baddi and Guwahati, is also on expansion by increasing its capacity in Guwahati unit.

Ozone Pharma, which has already presence in 21 countries, is also foreseeing 100 percent increase in its exports along with the overall growth. At present, exports account for just 10 percent of its total turnover. But the company will be augmenting its exports and focusing on UAE, GEC countries and UK more, Seghal said.

"Our core area is problem solution and we are on expansion, diversification and consolidation constantly. We stress on both horizontal and vertical growth always," he added. The group which has prescription drugs, OTC products, vaccines, and personal care products in the portfolio, took a modest beginning in 1992 with just Rs 3 crore. In 2001, it launched ayurvedic division which now has its own organic farming to meet the needs for raw materials.